KaloBios Pharma (KBIO) Tops Q2 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
KaloBios Reports Second Quarter Financial Results and Provides Clinical Update
August 10, 2015 8:01 AM EDTSOUTH SAN FRANCISCO, Calif., Aug. 10, 2015 /PRNewswire/ --Â KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO), a monoclonal antibody company focused on oncology, today announced its financial results for the second quarter of 2015 and provided an update on its clinical development progress.
Second Quarter 2015 Financial Results
Net loss for the quarter ended June 30, 2015 was $6.0 million or $1.46 per common share, as compared to $9.8 million or $2.38 per common share for the same period in 2014. All per-share amounts have been adjusted to reflect the... More
